GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company is starting four new pivotal trials this year.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company quietly deprioritises AlphaMedix.
Tecvayli and Hernexeos might get speedy approval decisions.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
